Prescription medicine
Methazolamide First approved as Neptazane
Methazolamide (Neptazane) is a prescription medicine with an FDA approval on record since 1959. FDA's NDC Directory lists it from 9 generic labelers, and pharmacies paid $0.627 per methazolamide 25 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the methazolamide FDA label on DailyMed (effective October 23, 2025, Bausch & Lomb Incorporated); the NDA 11721 record on Drugs@FDA; every methazolamide label on DailyMed.
Highlights of the record
FDA label of October 23, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageMethazolamide tablets are indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.
Forms and strengths
- 25 mg
- 50 mg
Tablet.
On the market
- Earliest approval on file
- January 26, 1959 Neptazane, Lederle; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 8 first June 30, 1993; 6 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 9 of which 9 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.627 per tablet Methazolamide 25 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 0 since 2013 0 Class I among all firms' recalls; 1 more by firms not listed as its makers
- FAERS reports
- 339 through July 30, 2026
What is methazolamide used for?
From the label: indications and usageMethazolamide tablets are indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.
Source: FDA drug label (Methazolamide), Bausch & Lomb Incorporated, effective October 23, 2025 (SPL set 0c0ba5c7-c53e-4e29-a7ff-48fddc5a9258), via openFDA; the full label on DailyMed
Is there a generic for methazolamide (Neptazane)?
The FDA approved the first generic methazolamide on June 30, 1993. 8 generic applications are approved; 6 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists methazolamide from 9 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1959 earliest approval on file
- 1993 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for methazolamide (Neptazane)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.627 per Methazolamide 25 mg tablet, down 34% from $0.952 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Methazolamide 25 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Methazolamide 25 mg tablet | Generic | $0.627 per tablet | $18.82 | -34% |
| Methazolamide 50 mg tablet | Generic | $1.47 per tablet | $44.05 | -3% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has methazolamide been recalled?
The FDA's Enforcement Report lists 1 recall naming methazolamide since 2013: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. 1 of them is by a firm that FDA's NDC Directory does not list as a maker of methazolamide and that holds no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup: METHAZOLAMIDE, Tablet, 50 mg may have potentially been mislabeled as the following drug: BUPRENORPHINE HCL SL, Tablet, 2 mg, NDC … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the methazolamide label say about other medicines?
The methazolamide label names 1 other medicine in its interaction, contraindication or warning sections. The labels of 1 other medicine name methazolamide. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aspirin | drug interactions | Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors (see WARNINGS ). |
Source: FDA drug label (Methazolamide), Bausch & Lomb Incorporated, effective October 23, 2025 (SPL set 0c0ba5c7-c53e-4e29-a7ff-48fddc5a9258), via openFDA; the full label on DailyMed
What do FAERS reports show for methazolamide?
The FDA Adverse Event Reporting System holds 339 reports that list methazolamide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 28 are coded as a death and 89 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Methazolamide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other